The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Elicio Therapeutics, Inc. (“Elicio” or “the Company”)...
NEW YORK , June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Elicio Therapeutics, Inc. ("Elicio" or the "Company") (NASDAQ: ELTX). Such investors are advised...
100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent...
Elicio Therapeutics reported Q1 2026 results showing a widening net loss and zero revenue days before its lead clinical program failed -- investors who bought ELTX lost 72.5% in a single session.
EPR Properties offers income investors a rare combination: a 6.3% monthly dividend yield, a conservative 73% payout ratio, and diversified exposure to experiential real estate well beyond movie theatres,...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.65%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.92%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.06%. June E-mini S&P...
The S&P 500 Index ($SPX ) (SPY ) today is up +1.67%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.79%. June E-mini S&P futures (ESM26...
The S&P 500 Index ($SPX ) (SPY ) today is up +1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +1.09%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.73%. June E-mini S&P futures (ESM26...
AMPLIFY-7P did not meet the pre-specified primary endpoint of disease-free survival (“DFS”) in the intent-to-treat population. Randomization balanced most prognostic factors between arms. However,...
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies...